(MMS) Maximus - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5779331041
Stock: Eligibility, Enrollment, Assessments, Contact Centers, Technology
Total Rating 36
Risk 94
Buy Signal -0.93
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.58% |
| Yield on Cost 5y | 2.00% |
| Yield CAGR 5y | 1.74% |
| Payout Consistency | 96.8% |
| Payout Ratio | 21.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.2% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | -8.68 |
| Character TTM | |
|---|---|
| Beta | 0.447 |
| Beta Downside | 0.413 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.37% |
| CAGR/Max DD | -0.07 |
Description: MMS Maximus January 10, 2026
Maximus, Inc. (NYSE:MMS) delivers outsourced government services across three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The Federal segment provides business-process outsourcing, eligibility and enrollment, clinical and technology solutions-including analytics, cybersecurity, and cloud modernization-for health and human-services programs. The U.S. Services segment focuses on eligibility support, multilingual contact centers, benefit counseling, and employment-service programs, while the Outside-the-U.S. segment offers similar BPS and technology offerings to international governments.
Key operating metrics that analysts watch include the company’s FY 2023 revenue of approximately $4.5 billion, up roughly 7 % YoY, driven largely by a 12 % increase in the Federal Services backlog. Gross margins have hovered near 24 %, reflecting the higher-margin technology and analytics contracts. A material macro driver is the U.S. federal budget outlook-particularly Medicaid and SNAP spending-which historically accounts for about 70 % of Maximus’ revenue and can swing earnings materially.
For a deeper dive into Maximus’ valuation metrics and peer comparison, the ValueRay platform offers a concise data sheet worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 319.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.27 > 1.0 |
| NWC/Revenue: 8.98% < 20% (prev 7.41%; Δ 1.57% < -1%) |
| CFO/TA 0.11 > 3% & CFO 429.4m > Net Income 319.0m |
| Net Debt (1.18b) to EBITDA (662.6m): 1.79 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.0m) vs 12m ago -7.31% < -2% |
| Gross Margin: 22.86% > 18% (prev 0.22%; Δ 2264 % > 0.5%) |
| Asset Turnover: 132.5% > 50% (prev 128.4%; Δ 4.02% > 0%) |
| Interest Coverage Ratio: 6.29 > 6 (EBITDA TTM 662.6m / Interest Expense TTM 84.1m) |
Altman Z'' 3.24
| A: 0.12 (Total Current Assets 1.25b - Total Current Liabilities 765.2m) / Total Assets 4.07b |
| B: 0.26 (Retained Earnings 1.06b / Total Assets 4.07b) |
| C: 0.13 (EBIT TTM 528.9m / Avg Total Assets 4.10b) |
| D: 0.70 (Book Value of Equity 1.67b / Total Liabilities 2.40b) |
| Altman-Z'' Score: 3.24 = A |
Beneish M -3.09
| DSRI: 1.00 (Receivables 902.0m/884.8m, Revenue 5.43b/5.31b) |
| GMI: 0.96 (GM 22.86% / 21.86%) |
| AQI: 0.99 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.02 (Revenue 5.43b / 5.31b) |
| TATA: -0.03 (NI 319.0m - CFO 429.4m) / TA 4.07b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of MMS shares?
As of February 08, 2026, the stock is trading at USD 75.08 with a total of 1,786,384 shares traded.
Over the past week, the price has changed by -20.50%, over one month by -15.75%, over three months by -9.25% and over the past year by +8.96%.
Over the past week, the price has changed by -20.50%, over one month by -15.75%, over three months by -9.25% and over the past year by +8.96%.
Is MMS a buy, sell or hold?
Maximus has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy MMS.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110 | 46.5% |
| Analysts Target Price | 110 | 46.5% |
| ValueRay Target Price | 77.5 | 3.2% |
MMS Fundamental Data Overview February 04, 2026
P/E Trailing = 17.1506
P/E Forward = 18.2482
P/S = 0.9491
P/B = 3.0773
P/EG = 2.0716
Revenue TTM = 5.43b USD
EBIT TTM = 528.9m USD
EBITDA TTM = 662.6m USD
Long Term Debt = 1.28b USD (from longTermDebt, last quarter)
Short Term Debt = 91.3m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.18b USD (from netDebt column, last quarter)
Enterprise Value = 6.38b USD (5.15b + Debt 1.44b - CCE 222.4m)
Interest Coverage Ratio = 6.29 (Ebit TTM 528.9m / Interest Expense TTM 84.1m)
EV/FCF = 17.41x (Enterprise Value 6.38b / FCF TTM 366.2m)
FCF Yield = 5.74% (FCF TTM 366.2m / Enterprise Value 6.38b)
FCF Margin = 6.74% (FCF TTM 366.2m / Revenue TTM 5.43b)
Net Margin = 5.87% (Net Income TTM 319.0m / Revenue TTM 5.43b)
Gross Margin = 22.86% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.19b) / Revenue TTM)
Gross Margin QoQ = 23.55% (prev 24.96%)
Tobins Q-Ratio = 1.57 (Enterprise Value 6.38b / Total Assets 4.07b)
Interest Expense / Debt = 1.55% (Interest Expense 22.4m / Debt 1.44b)
Taxrate = 25.06% (25.2m / 100.5m)
NOPAT = 396.4m (EBIT 528.9m * (1 - 25.06%))
Current Ratio = 1.64 (Total Current Assets 1.25b / Total Current Liabilities 765.2m)
Debt / Equity = 0.86 (Debt 1.44b / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = 1.79 (Net Debt 1.18b / EBITDA 662.6m)
Debt / FCF = 3.23 (Net Debt 1.18b / FCF TTM 366.2m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.78% (Net Income 319.0m / Total Assets 4.07b)
RoE = 18.87% (Net Income TTM 319.0m / Total Stockholder Equity 1.69b)
RoCE = 17.80% (EBIT 528.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.28b))
RoIC = 12.55% (NOPAT 396.4m / Invested Capital 3.16b)
WACC = 6.16% (E(5.15b)/V(6.60b) * Re(7.56%) + D(1.44b)/V(6.60b) * Rd(1.55%) * (1-Tc(0.25)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
[DCF Debug] Terminal Value 84.69% ; FCFF base≈372.9m ; Y1≈354.0m ; Y5≈337.7m
Fair Price DCF = 149.4 (EV 9.33b - Net Debt 1.18b = Equity 8.15b / Shares 54.5m; r=6.16% [WACC]; 5y FCF grow -6.60% → 2.90% )
EPS Correlation: 38.05 | EPS CAGR: -43.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.85 | Revenue CAGR: 3.69% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.02 | Chg30d=+0.070 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=8.17 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+11.0% | Growth Revenue=+0.7%
EPS next Year (2027-09-30): EPS=8.68 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+6.2% | Growth Revenue=+5.0%
P/E Forward = 18.2482
P/S = 0.9491
P/B = 3.0773
P/EG = 2.0716
Revenue TTM = 5.43b USD
EBIT TTM = 528.9m USD
EBITDA TTM = 662.6m USD
Long Term Debt = 1.28b USD (from longTermDebt, last quarter)
Short Term Debt = 91.3m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.18b USD (from netDebt column, last quarter)
Enterprise Value = 6.38b USD (5.15b + Debt 1.44b - CCE 222.4m)
Interest Coverage Ratio = 6.29 (Ebit TTM 528.9m / Interest Expense TTM 84.1m)
EV/FCF = 17.41x (Enterprise Value 6.38b / FCF TTM 366.2m)
FCF Yield = 5.74% (FCF TTM 366.2m / Enterprise Value 6.38b)
FCF Margin = 6.74% (FCF TTM 366.2m / Revenue TTM 5.43b)
Net Margin = 5.87% (Net Income TTM 319.0m / Revenue TTM 5.43b)
Gross Margin = 22.86% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.19b) / Revenue TTM)
Gross Margin QoQ = 23.55% (prev 24.96%)
Tobins Q-Ratio = 1.57 (Enterprise Value 6.38b / Total Assets 4.07b)
Interest Expense / Debt = 1.55% (Interest Expense 22.4m / Debt 1.44b)
Taxrate = 25.06% (25.2m / 100.5m)
NOPAT = 396.4m (EBIT 528.9m * (1 - 25.06%))
Current Ratio = 1.64 (Total Current Assets 1.25b / Total Current Liabilities 765.2m)
Debt / Equity = 0.86 (Debt 1.44b / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = 1.79 (Net Debt 1.18b / EBITDA 662.6m)
Debt / FCF = 3.23 (Net Debt 1.18b / FCF TTM 366.2m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.78% (Net Income 319.0m / Total Assets 4.07b)
RoE = 18.87% (Net Income TTM 319.0m / Total Stockholder Equity 1.69b)
RoCE = 17.80% (EBIT 528.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.28b))
RoIC = 12.55% (NOPAT 396.4m / Invested Capital 3.16b)
WACC = 6.16% (E(5.15b)/V(6.60b) * Re(7.56%) + D(1.44b)/V(6.60b) * Rd(1.55%) * (1-Tc(0.25)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
[DCF Debug] Terminal Value 84.69% ; FCFF base≈372.9m ; Y1≈354.0m ; Y5≈337.7m
Fair Price DCF = 149.4 (EV 9.33b - Net Debt 1.18b = Equity 8.15b / Shares 54.5m; r=6.16% [WACC]; 5y FCF grow -6.60% → 2.90% )
EPS Correlation: 38.05 | EPS CAGR: -43.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.85 | Revenue CAGR: 3.69% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.02 | Chg30d=+0.070 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=8.17 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+11.0% | Growth Revenue=+0.7%
EPS next Year (2027-09-30): EPS=8.68 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+6.2% | Growth Revenue=+5.0%